# MK-6194 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mk-6194

> MK-6194, sponsored by Merck & Co., Inc. (MRK): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | MK-6194 |
| Codes | MK-6194 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Systemic Lupus Erythematosus](https://sec-api.dev/indications/systemic-lupus-erythematosus) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 30, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Systemic Lupus Erythematosus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06161116 (Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-30 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-10." https://clinicaltrials.gov/study/NCT06161116

## Same indication

- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [Anifrolumab + apfs](https://sec-api.dev/pdufa/anifrolumab-apfs) (AZN)
- [BLINCYTO® (blinatumomab)](https://sec-api.dev/pdufa/blinatumomab) (AMGN)
- [Cadefrecitinib](https://sec-api.dev/pdufa/cadefrecitinib) (LKFT)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [MEDI-546](https://sec-api.dev/pdufa/medi-546) (AZN)
- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Sar441344 iv](https://sec-api.dev/pdufa/sar441344-iv) (SNY)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mk-6194.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MK-6194 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mk-6194

```bibtex
@misc{secapidev_pdufa_mk_6194_20261116,
  title        = {MK-6194 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mk-6194}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mk_6194_20261116","title":"MK-6194 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mk-6194","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
